



Contents lists available at SciOpen

Food Science and Human Wellness

journal homepage: <https://www.sciopen.com/journal/2097-0765>

Antiglycating effects of citrus flavonoids and associated mechanisms

Yunli Xiao^{a,1}, Junfeng Shen^{a,1}, Jianfeng Zhan^a, Limin Guo^b, Chi-Tang Ho^c, Shiming Li^{a,c,*}^a College of Biology and Agricultural Resources, Huanggang Normal University, Huanggang 438000, China^b Institute of Agro-Products Storage and Processing, Xinjiang Academy of Agricultural Sciences, Urumqi 830091, China^c Department of Food Science, Rutgers University, New Brunswick 08901, USA

ARTICLE INFO

Article history:

Received 26 June 2023

Received in revised form 20 July 2023

Accepted 27 August 2023

Keywords:

Citrus flavonoids

Hesperedin

Advanced glycation end products

Antiglycation

Diabetic complication

ABSTRACT

Glycation of proteins and DNA forms advanced glycation end products (AGEs) causing cell and tissue dysfunction and subsequent various chronic diseases, in particular, metabolic and age-related diseases. Targeted AGE inhibition includes scavengers of reactive carbonyl species (RCS) such as methylglyoxal (MG), glyoxalase-1 enhancers, Nrf2/ARE pathway activators, AGE/RAGE formation inhibitors and other antiglycating agents. Citrus flavonoids have demonstrated antioxidant and anti-inflammatory effects and are also found to be effective antiglycating agents. Herein, we reviewed the up to date progress of the antiglycation effects of citrus flavonoids and associated mechanisms. Major citrus flavonoids, hesperedin and its aglycone, hesperetin, inhibited glycation by scavenging MG forming mono- or di-flavonoid adducts with MG, enhanced the activity of glyoxalase-1, activated Akt/Nrf2 signal pathway while inhibiting AGE/RAGE/NF-κB pathway, reduced the formation of N^ε-(carboxymethyl)lysine (CML) and pentosidine, inhibited aldol reductase activity and decreased the levels of fructosamine. The antiglycating activity and mechanisms of other flavonoids was also summarized in this review. In conclusion, citrus flavonoids possess effective antiglycating activity via different mechanisms, yet there are many challenging questions remaining to be studied in the near future such as *in vivo* testing and human study of citrus flavonoids for efficacy, effectiveness and adverse effects of citrus flavonoids as a functional food in managing high levels of AGEs and controlling AGE-induced chronic diseases, diabetic complications in particular.

© 2024 Beijing Academy of Food Sciences. Publishing services by Tsinghua University Press.

This is an open access article under the CC BY-NC-ND license

<http://creativecommons.org/licenses/by-nc-nd/4.0/>.

1. Introduction

Happening ubiquitously *in vivo* and *in vitro*, glycation is a non-enzymatic reaction between carbonyl groups on reducing sugars and reactive carbonyl species (RCS) and free amino groups on amino acid residues of proteins, DNA and lipids. Products formed from direct addition and subsequent rearrangements, cyclization and/or dehydration are called advanced glycation end products (AGEs)^[1–2]. RCS, including methylglyoxal (MG) and glyoxal (GO), could

be generated *in vitro* from Maillard reaction and glucose auto-oxidation^[3] and *in vivo* through various metabolic pathways including the glycolysis^[4]. Due to the high electrophilic reactivity of RCS toward nucleophiles such as electron-rich amino groups on proteins, glycation happens rapidly once RCS are generated and AGEs formed. The carbonyl groups on reducing sugars are electron-deficient and readily attacked by amino residues on proteins to form AGEs. The most noticeable AGE is glycated hemoglobin (HbA_{1c}) found half century ago, a diagnostic biomarker for diabetes mellitus and diabetic complication^[5].

There have been reported pathological mechanisms that the accumulation of AGEs may seriously cause many physiological dysfunctions, particularly in a prolonged period of time^[6–7]. Exposure of dietary AGEs resulted in inflammation and associated diabetic angiopathy, whereas, restricted intake of dietary AGEs improved

¹ Authors contributed equally.

* Corresponding author at: College of Biology and Agricultural Resources, Huanggang Normal University, Huanggang 438000, China.

E-mail address: shiming@rutgers.edu (S.M. Li)

Peer review under responsibility of Tsinghua University Press.

SciOpen

Publishing services by Tsinghua University Press

insulin resistance in human type 2 diabetes^[8–10]. Due to the glycation, amino acid residues and proteins will alter even loss functionality and lead to oxidative stress induced age-related cataract and neurodegenerative diseases^[11], tissue injury^[12], cell apoptosis^[13–14] and others, resulting in many degenerative diseases^[11–12,14–15], such as cardiovascular disease^[16–18], cancer^[19], diabetic complications^[12,18,20–22], brain health problems^[23–26] and ageing among others^[26–28].

This review will start briefly with the mechanism of glycation and thus formed AGEs with proteins and DNA and then focus on the effective control of AGEs by citrus flavonoids via multiple mechanisms including trapping MG and other RCS, enhancing glyoxalase-1 activity, inhibiting AGE formation, scavenging formed AGEs, inhibiting the activity of AGE receptor (RAGE), and other associated pathways.

1.1 Glycation

Glycation happens when the amino acid residues of a protein react with a reducing sugar such as glucose and fructose. As depicted in Fig. 1, this non-enzymatic and spontaneous reaction occurs stepwise^[29]. The initial reaction is between an amino acid and a sugar forming an imine or Schiff's base, which undergoes rearrangement to generate a stable Amadori product (Fig. 1). The resulting Amadori product generates different types of dicarbonyl compounds after cleavage at different bonds on the sugar moiety. Thus yielding dicarbonyl compounds, i.e. reactive carbonyl species including glyoxal, methylglyoxal, glucosone, 3-deoxyglucosone and others, are very reactive due to their electron deficient nature and readily attacked by electron-rich nucleophiles, such as side chain amino groups of amino acid residues on a protein. This is the glycation process that forms AGEs^[29–30].

Fig. 2 illustrates several common examples of such AGE compounds formed from MG and arginine- or lysine-containing proteins, such as *N*^ε-(5-methyl-4-imidazol-2-yl)-*L*-ornithine (MG-H1) from arginine and MG, 2-amino-5-(2-amino-5-hydro-5-methyl-4-imidazol-1-yl)pentanoic acid (MG-H2) from arginine and MG, *N*^ω-(carboxylethyl)arginine (CEA) from arginine and MG, *N*^ε-(carboxymethyl)lysine (CML) from lysine and GO, and *N*^ε-(carboxylethyl)lysine (CEL) from lysine and MG; 6-[1-[(5S)-

5-ammonio-6-oxido-6-oxohexyl]-4-methyl-imidazolium-3-yl]-*L*-norleucine (MOLD) from lysine dimer and MG; 2-ammonio-6-[(2-[4-ammonio-5-oxido-5-oxopentyl] amino)-4-methyl-4,5-dihydro-1H-imidazol-5-ylidene]amino)hexanoate (MODIC) from lysine, arginine and MG, and others, among which MG-H1 is a major methylglyoxalated protein derived AGEs^[30–31]. For example, MG-H1 accounts for about 1%–2% of arginine-containing proteins in mammalian tissue, plasma, and extracellular matrix proteins^[32]. MG-H1 is the most abundant AGEs in aged human lenses and levels could reach 6 nmol/mg proteins. Glycated human lens proteins (AGEs) could stimulate further glycation, oxidation, and protein aggregation, leading to cataract formation^[30]. In elder people without diabetes, MG-H1 was the most abundant AGE in bone compared to non-MG derived AGEs^[18]. Immunoglobulins contain about 75% lysine residue, which is susceptible to glycation forming AGEs, resulting in the loss of bind affinity with antigens and its immune functionality^[20–21].

Upon the modification by MG, proteins will lose or alter their original biofunctionality because of the compositional and conformational structure change of proteins such as cross-link of extracellular and cellular proteins. Fig. 2 also demonstrated common AGEs from MG and DNA, such as MG reacting with 2-deoxyguanosine generating *N*²-(1-carboxylethyl)-2'-deoxyguanosine (CEdG) and with 2'-deoxyadenosine forming *N*⁶-(1-carboxylethyl)-2'-deoxyadenosine (CEdA)^[33–34].

1.2 Inhibition of RCS and AGE by phytochemicals

Clearance of RCS and AGEs with phytochemicals has been broadly studied, particularly with polyphenolic compounds. Tea polyphenols could effectively trap MG in simulated physiological conditions to form mono- and di-MG adducts with catechins and theaflavins^[31,35]. Both rutin and its aglycone quercetin expressed antiglycation effects by decreasing the levels of protein carbonyl groups and inhibited the formation of AGEs in a concentration dependent manner, but rutin has demonstrated more potent effects of antiglycation than quercetin^[36]. Dietary myricetin and its mono- and di-methylated *in vivo* metabolites effectively trapped MG forming mono- and di-MG adducts, demonstrated the efficacy of myricetin in scavenging MG after myricetin-fruits/vegetables consumption^[37].




Fig. 1 Formation of RCS.




Fig. 2 Structures of common AGEs from MG and protein and DNA.

In diabetic patients, high blood sugar and its *in vivo* derived RCS such as MG, GO and 3-deoxyglucosone trigger glycation reaction, which continues even the levels of glucose are reduced^[38]. Baicalein from *Scutellaria baicalensis* has efficiently inhibited the glycation of human serum albumin (HSA), marked by the reduced levels of AGE after addition of baicalein to a pre-incubated MG-containing HSA^[39]. Phlorotannis in brown algae *Fucus vesiculosus* also inhibited the glycation of bovine serum albumin (BSA) by 50% in 2 h^[40]. The effective RCS trapping and inhibition of AGE formation have been demonstrated by other phytochemicals such as stilbene compounds to prevent diabetes complication^[41–42].

1.3 Citrus flavonoids

Citrus fruits in general are the most-grown fruits globally, contributing to various health-promoting and valuable phytochemicals. Belonging to the family of Rutaceae, the major species and main industrialized citrus crops include oranges, mandarins, grapefruits and lemons among others^[43–44]. Citrus processing for juice and concentrated products makes up one third or more of total citrus consumption, thus massive amounts of citrus peels are left wasted. Actually, intensive research from the past two decades has demonstrated that there are many food bioactives in citrus peels, such as essential oils, flavonoids and other polyphenolic compounds, organic acids, polysaccharides, dietary fiber and other valuable phytochemicals^[43]. Citrus fruits as a whole are a rich source of flavonoids, majorly flavanones (Table 1) and a certain amount of polymethoxyflavones can also be found in citrus peels (Fig. 3)^[45]. It is demonstrated that citrus flavonoids have antioxidant^[44,46–49], anti-obesity^[50–51], inhibition of chronic inflammation^[46,52–53], anti-cancer^[54–56], protective effects against brain-injury^[57–58], Alzheimer's^[53,59–61] and Parkinson's diseases^[61], anti-diabetic effects^[62–64], regulation of gut microbiota^[44,51,65] and anti-ageing activity^[66–67]. In addition, citrus flavonoids have been found recently to have effective anti-glycation

properties^[63,68]. This review will be focused on the inhibitory effects of citrus flavonoids, particularly, hesperidin and PMFs on glycation.

2. Anti-glycation of citrus flavonoids

In searching for effective agents to inhibit glycation and disease prevention, much research has been dedicated to natural products, such as tea and other polyphenols^[35,69]. In this review, we concentrated on the anti-glycation activity and associated mechanisms of citrus flavonoids.

2.1 Citrus flavonoids scavenging RCS

In citrus flesh and peels, hesperidin is one of the richest flavonoids^[65–66]. It has been demonstrated that hesperidin has antioxidant^[70], inhibitory effects on inflammation^[47,70], and protective effects against CVD, among others^[71]. For instance, a recent human study with hesperidin enriched orange juice consumption reduced insulin resistance and the expression of proinflammatory genes after a 12-week treatment^[72]. Hesperidin regulated mineralized tissue formation through the mechanism of osteoblast cell differentiation and matrix organization, a potential adjunct therapy in bone regeneration^[73]. Moreover, hesperidin has strong anti-glycation effects and hence can ameliorate multiple AGE-related chronic diseases. The anti-glycation effects of hesperidin is the most studied among citrus flavonoids. Numerous research results have associated RCS-induced AGEs with improvement in diabetes complication. Commercial anti-diabetes drugs can control blood sugar but usually cannot prevent diabetes-related complications. As it was discussed in the introduction, reducing the formation of AGEs by scavenging its precursor–RCS, MG in particular and removing formed AGEs in a bio-system are two of the strategies to prevent diabetes complications. Hesperidin possesses strong antioxidant effects, and thus can effectively scavenge reactive oxygen species (ROS). Owing to its nucleophilic structural nature, it can react and remove RCS rapidly to

identified as primarily mono-6-MG-hesperedin. The stereo center at 2-position and loss of rutinosyl group yielded more than expected peaks in liquid chromatography.^[68] Structures of MG adducts with hesperedin and hesperetin are depicted in Fig. 4.^[78-79] Hesperetin is an aglycone of hesperedin. The release of the 7-*O*-rutinosyl sugar group also enhances the nucleophilic attack at 6- and 8-position of hesperetin and subsequent formation of a stable hemiacetal 5-member ring structure between MG and hesperetin at 6- and 5-positions; or 8- and 7-positions, which mostly rendered two mono-MG-hesperetin adducts. Similar to other adducts identified between MG and polyphenolic compounds such as tea catechins, MG-hesperedin/hesperetin adducts are in the most stable form, but were only identified from liquid chromatography and mass spectroscopy. Further characterization is warranted to discover definitive structures. Fig. 4 also illustrates the deduced structures of adducts between MG and another citrus flavonoid—diosmetin, from which we can see that the nucleophilic reaction occurred at 6- or 8-position for mono MG addition or at both 6- and 8-position for di-MG addition.^[78] It should be reminded that all the adduct structures in Fig. 4 have regioisomers, thus NMR confirmation is required to illustrate the yielded structures of MG adducts with citrus flavonoids with much confidence.




Fig. 4 Adducts of MG and hesperidin and hesperetin^[78–79].

2.2 Citrus flavonoids enhancing Glo-1 activity, activating Nrf2/ARE pathway and inhibiting AGE/RAE/NF- κ B pathway

1,2-Dicarbonyl (or α -dicarbonyl) aldehydes are the most reactive class of RCS, such as methylglyoxal and glyoxal generated *in vitro* from the Maillard reaction, glucose auto-oxidation (Fig. 1) or endogenously from the glycolytic pathway by nonenzymatic degradation of triosephosphates, glyceraldehyde-3-phosphate (GA3P) and dihydroxyacetonephosphate (DHAP) in anaerobic glycolysis, gluconeogenesis, glyceroneogenesis and photosynthesis^[80]. As mentioned in previous sections, α -dicarbonyl aldehydes are highly reactive and readily react with electron rich amino groups on proteins and DNA, leading to glycation and consequent pathological process of chronic diseases such as diabetic complication. Glyoxalase 1 (Glo-1) and glyoxalase 2 (Glo-2) in the body play pivotal roles in the clearance and detoxication of α -dicarbonyl aldehydes, among which Glo-1 is the rate-limiting enzyme. In the presence of glutathione (GSH) as a cofactor, Glo-1 rapidly removes methylglyoxal under normal physiological conditions. In pathological conditions such as hyperglycemia, enhancing the activity of Glo-1 by a drug or nutrient is another strategy to remove MG and GO^[80]. Indeed, Glo-1 over expression has been reported to improve the pathological features of diabetic complications^[81–82]. Glo-1 is controlled by transcription factor-nuclear factor erythroid-2-related factor 2 (Nrf2)/anti-oxidant response through regulatory antioxidant response element (ARE) pathway. Elevated MG levels in hyperglycemia conditions induce oxidative stress, which consequently cause down-regulation of Glo-1 leading to increased levels of AGE^[83]. Existing in the cell membrane, the receptor for advanced glycation end products (RAGE) was discovered as a signal transduction receptor for AGEs such as CEL. AGEs bind to RAGE and consequently trigger the nuclear factor κ B (NF- κ B) signaling pathway, inducing inflammatory response and causing oxidative stress and a cascade of biological consequences, such as cell damage^[84].

Hesperidin was found to have activated the Akt/Nrf2 signal pathway and inhibited the RAGE/NF- κ B pathway^[85]. In a 90-day APP/PS mouse study with a dose of 40 mg/kg, hesperidin effectively reduced levels of ROS, lipid peroxidation, protein glycation and 8-OHdG, while increasing the activity of HO-1, superoxide dismutase (SOD), catalase, and glutathione peroxidase, overall significantly suppressing oxidative stress, leading to protective effects of neuroinflammation and against Alzheimer disease (AD)^[85].

Hesperetin, the aglycone of hesperidin, occurs naturally in citrus fruits in a much smaller content than hesperidin, but can be increased dramatically as a metabolite of hesperidin after ingestion of citrus fruits or citrus juice that contains relatively larger amount of hesperidin. It has been reported that hesperetin combined with resveratrol improved metabolic and vascular health in overweight and obese human subjects as a Glo-1 inducer^[86]. More importantly, this co-formulation of hesperetin and resveratrol significantly increased the expression and activity of Glo-1 by 27%, decreased the level of plasma MG by 237%, reduced the total protein glycation by 214%, decreased fasting glucose by 25% and increased oral glucose sensitivity index by 42 mL/(min·m²)^[86], indicating the great efficaciousness of hesperetin and resveratrol in scavenging MG and reducing AGE formation.

As above-mentioned, α -dicarbonyl aldehydes and their detoxifying enzyme Glo-1 play a vital role in the pathogenesis of diabetic complications, including nephropathy, neuropathy and depression, among others. A recent study revealed that hesperidin effectively ameliorated behaviors of depression and anxiety of diabetic rats, attributing to the enhancement of Glo-1 in scavenging MG and GO, etc. α -Dicarbonyl aldehydes and the activation of the Nrf2/ARE pathway^[87]. In this controlled study, treatment containing hesperidin to diabetic rats induced by streptozotocin at a dose of 50 or 150 mg/kg led to many behavior changes toward normality, such as decreased immobility time in a forced swimming test and increased entry percentage and time spent in open arms in a maze test. More importantly, hesperidin enhanced Glo-1 activity, inhibited the AGEs/RAGE axis and oxidative stress in the brain, and significantly increased the Nrf2 levels and upregulated g-glutamylcysteine synthetase, demonstrating the antidepressant and anxiolytic effects of hesperidin in diabetic rats^[87]. The renoprotective effects of hesperetin in diabetic nephropathic rats induced by streptozotocin have been evaluated and found that hesperetin at a dose of 50 or 150 mg/kg effectively ameliorated the renal morphological changes and improved renal functions and structural changes of the diabetic rats^[62]. This study demonstrated that hesperetin treatment up-regulated the expression of Glo-1 and enhanced Glo-1 activity, reversed the declined levels of Nrf2, and significantly increased levels of Nrf2 at both dosages. High dosage of hesperetin significantly facilitated the phosphorylation of Nrf2, thus remarkably raising the levels of p-Nrf2 in nucleus^[62]. Furthermore, hesperetin significantly up-regulated the expression levels of γ -glutamylcysteine synthetase (γ -GCS), a downstream gene regulated by the Nrf2/ARE pathway,

confirming the Nrf2/ARE pathway activation by hesperetin. This study also found that hesperetin decreased AGE content and RAGE expression in the renal cortex of diabetic rats and inhibited IL-1 β and TNF- α inflammatory cytokines significantly, further confirming the inhibitory effects of AGEs/RAGE related inflammation axis^[62].

2.3 Citrus flavonoids inhibiting glycation and AGE formation

In addition to direct scavenging of RCS and enhancing Glo-1 activity, activating Nrf2/ARE pathway and inhibiting AGE/RAGE/NF- κ B pathway by citrus flavonoids, there are a number of reports that have demonstrated the anti-glycation effects of citrus flavonoids or citrus extracts by inhibiting the formation of AGEs and/or degrading the formed AGEs back to proteins.

When lysine residue is glycated by GO, the product is CML (Fig. 2). It has been reported that hesperedin reduced the content of CML compared to the model group^[88] in a study that investigated the inhibitory effects of AGEs by hesperedin in a rheumatoid arthritis (RA) model. There were large amounts of free radicals produced in the RA model. These free radicals, ROS in particular, acted as active glycation agents after intra-structure rearrangements or other alterations^[88], from which AGEs formed were increased dramatically after the injection of collagen type II suspension to Wistar rats. In the 21-day oral feeding study, hesperedin significantly inhibited bone loss, reduced the levels of CML and pentosidine (an AGE) concentrations significantly by hesperedin, by 20% (CML) and 26% (pentosidine) in plasma; and 21% and 16% in IgG, respectively. Therefore, the RA alleviation of hesperedin was achieved by scavenging ROS, inhibiting inflammation and also reducing the levels of AGEs^[88]. A mouse study using human lens epithelial cell lines and mouse lens organ cultures found that AGEs in lens proteins increased with age. However, hesperetin at 50 or 100 μ mol/L prevented the formation of AGEs and CML and also the modification of lens proteins in a dose-response manner^[68]. In addition, hesperetin treatment also prevented lens hardening and decreased chaperone activity of lens proteins. Taken together, it has suggested that hesperetin and its derivatives could be agents for the prevention of presbyopia and cataracts^[68].

It has been known that oxidative stress and glycation are closely associated with diabetes complications. Also, serum fructosamine, a circulating glycated protein, is formed from the glycation of mostly albumin, and the levels of fructosamine can provide an estimate of the average blood glucose levels in the preceding 2–3 weeks. It has been shown that fructosamine correlates more consistently with continuous glucose monitoring than hemoglobin A1c (HbA1c), first identified AGE from diabetes patients more than 5 decades ago^[5,89]. An *in vitro* study using human serum albumin has found that hesperedin at 50 μ mol/L decreased the content of fructosamine by 40% and inhibited AGE formation by 71%^[90], indicating the effective antioxidant and anti-glycation effect of hesperedin. Another *in vitro* study with ROS-induced oxidative stress in L6 myotubes, both hesperedin and hesperetin effectively reduced oxidative stress by scavenging intracellular ROS and up-regulating antioxidant defense system such as SOD and GPX. At 10 μ mol/L, hesperedin and hesperetin inhibited protein glycation by 65.6% and 35.6%, respectively; significantly reduced the formation of AGEs, demonstrating that hesperedin and hesperetin, as functional food ingredients, could effectively suppress

diabetic pathophysiology mediated by oxidative stress^[63]. The complex of hesperetin-Cu (II) also demonstrated strong anti-glycation effects. In a BSA-fructose system, simplified mimicking diabetic complications model, the hesperetin-Cu (II) complex inhibited AGE formation by more than 88%, more effective than hesperetin (51%) and aminoguanidine (22%). The complex also reduced the levels of BSA carbonylation and oxidation, inhibited BSA crosslinking by 66%, scavenged 79% hydroxyl radical, and removed 85% MG after co-incubation, indicating that the hesperetin-Cu (II) complex could have a close interaction with BSA, strong MG scavenging capability, and effective removal of free radicals^[91]. Also in the BSA-fructose model, pomelo extract, containing neohesperedin, hesperedin, naringin and naringenin in amounts of 25.4, 12.0, 11.0 and 9.2 mg/g measured by high-performance liquid chromatography, respectively, significantly decreased the fructosamine content and inhibited the formation of AGE and CML in a concentration-dependent manner^[92]. Poncirin, another flavanone from citrus fruits, has been investigated for its anti-diabetic activity and associated mechanisms, including inhibitory effect against protein tyrosine phosphatase 1B, α -glucosidase, human recombinant aldose reductase, rat lens aldose reductase and AGE formation with respective IC₅₀ values of 7.76, 21.31, 3.56, 11.91 and 3.23 μ mol/L^[92]. In a C2C12 cell study, poncirin significantly increased glucose uptake, decreased PTP1B expression, and consequently, increased the level of GLUT-4 expression by activating IRS-1/PI3K/Akt/GSK-3 signaling pathway. More importantly, during 4 weeks of study, poncirin effectively inhibited the formation of fluorescent AGE, CML, fructosamine and β -cross amyloid in a BSA glycation model induced by glucose-fructose^[93].

Polymethoxyflavones (PMFs) from citrus peels have attracted great attention due to their multiple biological activities such as antioxidant^[45,47,49,94], inhibition of inflammation^[47,52,94–95], anti-cancer^[54–56] and prevention of Alzheimer's disease^[96–97] among others. However, the anti-glycation activity of PMFs was rarely explored. Ubiquitously existing in the peels of citrus genus, 5-demethylnobiletin significantly inhibited protein glycation (IC₅₀ 64.2 μ mol/L), more effectively than aminoguanidine (IC₅₀ 484.3 μ mol/L), through preventing the formation of fructosamine adducts and also dicarbonyl generation^[98]. This is the first time that a PMF was identified as an effective AGE inhibitor. Further investigations on the AGE formation by PMFs and associated mechanisms elucidation are warranted.

2.4 Citrus flavonoids alleviated AGE induced stress

Formed AGEs cause pathological changes in the body and result in various diseases^[6,12]. As aforementioned, citrus flavonoids have been reported to scavenge RCS directly and to elevate Glo-1's activity to quickly clear MG, GO and other α -dicarbonyl compounds, effectively reducing the formation of AGEs. However, AGEs already formed and existing in the body are slowly metabolized. In the meantime, pathophysiological conditions induced by AGEs need to be addressed to avoid potential tissue damage and chronic disease conditions.

It has been observed that treatment of human SH-SY5Y neuroblastoma cells with AGEs in BSA triggered ROS overproduction and elevated levels of SOD, GPX and catalase, but hesperetin treatment effectively reduced the overproduction of ROS and decreased the levels of SOD, GPX and catalase, down-regulated the

expression of amyloid precursor protein and decreased β -amyloid ($A\beta$) production^[99]. Furthermore, the application of hesperedin at 40 $\mu\text{mol/L}$ significantly mitigated the expression of endoplasmic reticulum stress proteins induced by AGEs at a range of 50–250 $\mu\text{g/mL}$ in BSA, hence, hesperedin played a crucial role in attenuating glycation-induced $A\beta$ neurotoxicity and preventing Alzheimer's disease^[99]. Another citrus flavonoid, diosmetin, also demonstrated the alleviating effect against AGE-induced AD-like pathology. At a concentration of 10 $\mu\text{mol/L}$, diosmetin treatment of human SH-SY5Y cells stimulated with 200 $\mu\text{g/mL}$ of AGEs effectively inhibited the overproduction of ROS and down-regulated the expression of antioxidant enzymes such as SOD, GPX and catalase. Diosmetin also reversed amyloid precursor protein upregulation and increased production of amyloid- β , which was triggered by AGEs^[100]. Diosmetin pre-treatment of SH-SY5Y cells prevented endoplasmic reticulum (ER) stress response to AGEs^[100], thereby protecting neuroblastoma cells from ER injury induced by AGEs.

3. Other methods of alleviating AGEs and RAGE expression

As mentioned in previous sections, citrus flavonoids inhibited AGE formation and accumulation and could potentially prevent pathophysiological diseases via the scavenging of MG, GO, 3-GD and other RCS, prevention of oxidative stress, inhibition of fructosamine formation and aldose reductase activities, elevation of Glo-1 activity, inhibition of AGE formation and removal of formed AGEs among others. Other methods to control AGEs also include inhibition of RAGE formation^[101–102], degradation of AGEs/RAGE by ubiquitin-proteasome system^[103–105], autophagy^[106–108] and physical exercise^[109] combined with diet intervention^[110]. Recent reviews briefly summarized the mechanisms targeting the inhibition and scavenging of AGEs^[111–112]. However, due to the nature of multiplicity of the glycation process, an anti-glycation agent often plays multi-functional roles at different stages of glycation in preventing the damage caused by AGEs.

For instance, citrus flavonoids naringin and its aglycone naringenin have demonstrated their anti-glycating property in an incubated mixture of HSA, ribose and GO^[113]. Both naringin and naringenin effectively inhibited the glycation of HSA by GO, marked by the significant decrease of the absorbance intensity of AGEs formed between HSA and GO at all three wavelength (335, 350 and 370 nm) tested by comparing to that of a reaction system with no flavonoids added^[113]. In addition to expected anti-glycating mechanisms of these two citrus flavonoids such as antioxidation and direct trapping of GO, hydrogen bonding between flavonoids and HSA, and interactions between arginine and lysine residues and GO also prevented GO glycation HSA. It has been found that naringenin had stronger antiglycating than naringin for it binds to HSA sub-domains IIA and IIIA, whereas naringin only binds to HSA subdomain IIA. It is of great importance to investigate the inhibitory effects of HSA glycation by agents like citrus flavonoids because HSA is almost the most prevalent protein in the plasma and extremely susceptible to glycation. Furthermore, the two citrus flavonoids dramatically decreased the presence of fibrillar aggregates generated from HSA modification by GO and ribose^[113].

In the polyol pathway, aldose reductase is enhanced in the hyperglycemic conditions, which results in overproduction of sorbitol

and fructose that in turn converts to fructosamine and other AGEs, subsequently causing diabetic complications^[114]. Therefore, inhibition of aldol reductase is one of the important strategies to control diabetes complications. In a recent enzyme binding assay with aldol reductase, naringenin has demonstrated inhibitory effects of aldose reductase with an IC_{50} of 2.6 $\mu\text{mol/L}$. At a concentration of 10 $\mu\text{mol/L}$, naringenin reduced the content of fructosamine by more than 31% and inhibited the production of fluorescent AGEs by 93%^[115], indicating that naringenin can inhibit aldose reductase efficiently. From the aforementioned, we can see that naringenin has effective anti-glycation effects through multiple pathways^[113,115]. Therefore, the mechanism of anti-glycation activity of citrus flavonoids such as hesperedin, naringin and their aglycones, has been found to be multidimensional.

4. Concluding remarks

Mounting evidence has attested that excessive AGEs are linked to numerous age-related diseases, particularly diabetes complication, cardiovascular and Alzheimer's diseases, while people with hyperglycemia produce more AGEs but have a slower clearance rate, resulting in the accumulation of AGEs in their bodies. Current strategies reducing AGEs include trapping RCS, enhancing Glo-1 activity, inhibiting glycation, reducing aldose reductase activity, degrading formed AGEs/RAGE, and activating the Nrf2/ARE pathway and inhibiting the AGE/RAGE/NF- κB pathway, autophagy, and exercise, among others. It has been demonstrated that citrus flavonoids such as hesperedin, hesperetin, naringin, naringenin, diosmetin, neohesperedin and polymethoxyflavones were involved in one or multiple pathways aforementioned in reducing AGEs and related detrimental effects. However, many challenges remain to be solved in addressing the antiglycation effects and associated mechanisms of citrus flavonoids, particularly in the efficacy and long term effectiveness in human consumption as functional foods.

Conflict of interest

Chi-Tang Ho is a senior editor, and Shiming Li is a scientific editor for *Food Science and Human Wellness* and were not involved in the editorial review or the decision to publish this article. None of the authors have any conflict of interest.

Acknowledgement

Authors received support from the High Level Scientific Research Cultivation Project of Huanggang Normal University (202108504) and from the National Natural Science Foundation of China (31571832)

References

- [1] A. Moraru, J. Wiederstein, D. Pfaff, et al., Elevated levels of the reactive metabolite methylglyoxal recapitulate progression of type 2 diabetes, *Cell Metab.* 27 (2018) 926–934. <https://doi.org/10.1016/j.cmet.2018.02.003>.
- [2] R. Ramasamy, S.F. Yan, A.M. Schmidt, Methylglyoxal comes of AGE, *Cell* 124 (2006) 258–260. <https://doi.org/10.1016/j.cell.2006.01.002>.
- [3] J.A. Lin, C.H. Wu, G.C. Yen, Perspective of advanced glycation end products on human health, *J. Agric. Food Chem.* 66 (2018) 2065–2070. <https://doi.org/10.1021/acs.jafc.7b05943>.

- [4] P.J. Thornalley, Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification—a role in pathogenesis and antiproliferative chemotherapy, *Gen. Pharmacol.* 27 (1996) 565-573. [https://doi.org/10.1016/0306-3623\(95\)02054-3](https://doi.org/10.1016/0306-3623(95)02054-3).
- [5] R.J. Koenig, C.M. Peterson, R.L. Jones, et al., Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus, *N. Engl. J. Med.* 295 (1976) 417-420. <https://doi.org/10.1056/NEJM197608192950804>.
- [6] C.G. Schalkwijk, C.D.A. Stehouwer, Methylglyoxal, a highly reactive dicarbonyl compounds, in diabetes, its vascular complications, and other age-related diseases, *Physiol. Rev.* 100 (2020) 407-461. <https://doi.org/10.1152/physrev.00001.2019>.
- [7] N. Rabbani, M. Xue, P.J. Thornalley, Dicarbonyl stress, protein glycation and the unfolded protein response, *Glycoconjugate J.* 38 (2021) 331-340. <https://doi.org/10.1007/s10719-021-09980-0>.
- [8] H. Vlassara, W. Cai, S. Goodman, et al., Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1, *J. Clin. Endocrinol. Metab.* 94 (2009) 4483-4491. <https://doi.org/10.1210/jc.2009-0089>.
- [9] H. Vlassara, W. Cai, J. Crandall, et al., Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy, *Proc. Natl. Acad. Sci. USA* 99 (2002) 15596-15601. <https://doi.org/10.1073/pnas.242407999>.
- [10] J. Uribarri, W. Cai, M. Ramdas, et al., Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes, *Diabetes Care* 34 (2011) 1610-1616. <https://doi.org/10.2337/dc11-0091>.
- [11] X. Fan, D.R. Sell, C. Hao, et al., Vitamin C is a source of oxoaldehyde and glycativ stress in age-related cataract and neurodegenerative diseases, *Aging Cell.* 19 (2020) e13176. <https://doi.org/10.1111/acel.13176>.
- [12] P.J. Beisswenger, S.K. Howell, G.B. Russell, et al., Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products, *Diabetes Care* 36 (2013) 3234-3239. <https://doi.org/10.2337/dc12-2689>.
- [13] S.Y. Kassim, M.A. Alaoui-Jamali, J. Génest J, et al., Advanced glycation end products (AGEs) promote apoptosis via a novel pathway: involvement of CAAT/enhancer-binding protein β (C/EBP β), JNK, and caspase-3, *Diabetes* 55 (2006) 216-226. <https://doi.org/10.12659/MSM.915806>.
- [14] J. Chen, J. Zing, S. Yu, et al., Advanced glycation end products induce apoptosis of endothelial progenitor cells by activating receptor RAGE and NADPH oxidase/JNK signaling axis, *Am. J. Transl. Res.* 8 (2016) 169-178.
- [15] V.P. Reddy, P. Aryal, P. Soni, RAGE inhibitors in neurodegenerative diseases, *Biomedicine* 11 (2023) 1131. <https://doi.org/10.3390/biomedicine11041131>.
- [16] G. Basta, A.M. Schmidt, R. de Caterina, Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes, *Cardiovasc. Res.* 63 (2004) 582-592. <https://doi.org/10.1016/j.cardiores.2004.05.001>.
- [17] M. Brownlee, Biochemistry and molecular cell biology of diabetic complications, *Nature* 414 (2001) 813-820. <https://doi.org/10.1038/414813a>.
- [18] S.L. Fishman, H. Sonmez, C. Basman, et al., The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review, *Mol. Med.* 24 (2018) 59. <https://doi.org/10.3390/biomedicine11041131>.
- [19] S.W.T. Lai, E.D.J.L. Gonzalez, T. Zoukari, et al., Methylglyoxal and its adducts: induction, repair, and association with disease, *Chem. Res. Toxicol.* 35 (2022) 1720-1746. <https://doi.org/10.1021/acs.chemrestox.2c00160>.
- [20] J. Koska, H.C. Gerstein, P.J. Beisswenger, et al., Advanced glycation end products predict loss of renal function and high-risk chronic kidney disease in type 2 diabetes, *Diabetes Care* 45 (2022) 684-691. <https://doi.org/10.2337/dc21-2196>.
- [21] A. Gul, M.A. Rahman, A. Salim, et al., Advanced glycation end products in senile diabetic and nondiabetic patients with cataract, *J. Diabetes Complications* 23 (2009) 343-348. <https://doi.org/10.1016/j.jdiacomp.2008.04.001>.
- [22] N.M.J. Hanssen, J. Westerink, J.L.J.M. Scheijen, et al., Higher plasma methylglyoxal levels are associated with incident cardiovascular disease and mortality in individuals with type 2 diabetes, *Diabetes Care* 41 (2018) 1689-1695. <https://doi.org/10.2337/dc18-0159>.
- [23] V.N. Bukke, R. Villani, A. Moola, et al., The glucose metabolic pathway as a potential target for therapeutics: crucial role of glycosylation in Alzheimer's disease, *Int. J. Mol. Sci.* 21 (2020) 7739. <https://doi.org/10.3390/ijms21207739>.
- [24] J. Chen, S.S. Mooldijk, S. Licher, et al., Assessment of advanced glycation end products and receptors and the risk of dementia, *JAMA Network Open* 4 (2021) e2033012. <https://doi.org/10.1001/jamanetworkopen.2020.33012>.
- [25] A. Puddu, R. Sanguineti, K. Montecucco, et al., Advanced glycation end-products and Alzheimer's disease, *J. Alzheimer's Dis.* 35 (2013) 403-413. [https://doi.org/10.1016/S0002-9440\(10\)65659-3](https://doi.org/10.1016/S0002-9440(10)65659-3).
- [26] J. Chaudhuri, Y. Bains, S. Guha, et al., The role of advanced glycation end products in aging and metabolic diseases: bridging association and causality, *Cell Metab.* 28 (2018) 337-352. <https://doi.org/10.1016/j.cmet.2018.08.014>.
- [27] D. Sergi, H. Boulestin, F.M. Campbell, et al., The role of dietary advanced glycation end products in metabolic dysfunction, *Mol. Nutr. Food Res.* 65 (2021) 1900934. <https://doi.org/10.1002/mnfr.201900934>.
- [28] M. Fournet, F. Bonte, A. Desmouliere, Glycation damage: a possible hub for major pathophysiological disorders, *Aging Dis.* 9 (2018) 880-900. <https://doi.org/10.14336/AD.2017.1121>.
- [29] C.Y. Lo, S. Li, D. Tan, et al., Trapping reactions of reactive carbonyl species with tea polyphenols in simulated physiological conditions, *Mol. Nutr. Food Res.* 50 (2006) 1118-1128. <https://doi.org/10.1002/mnfr.200600094>.
- [30] N. Ahmed, P.J. Thornalley, J. Dawczynski, et al., Methylglyoxal-derived hydroimidazolone advanced glycation end-products of human lens proteins, *Invest. Ophthalmol. Vis. Sci.* 44 (2003) 5287-5292. <https://doi.org/10.1167/iovs.03-0573>.
- [31] Y. Luo, J. Zhang, C.T. Ho, et al., Management of Maillard reaction-derived reactive carbonyl species and advanced glycation end products by tea and tea polyphenols, *Food Sci. Hum. Well.* 11 (2022) 557-567. <https://doi.org/10.1016/j.fshw.2021.12.012>.
- [32] N. Rabbani, P.J. Thornalley, Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome, *Amino Acids* 42 (2012) 1133-1142. <https://doi.org/10.1007/s00726-010-0783-0>.
- [33] M. Frischmann, C. Bidmon, Identification of DNA adducts of methylglyoxal, *Chem. Res. Toxicol.* 18 (2005) 1586-1592. <https://doi.org/10.1021/tx0501278>.
- [34] D. Tamae, P. Lim, G.E. Wuenschell, et al., Mutagenesis and repair induced by the DNA advanced glycation end product N^2 -1-(carboxyethyl)-2-deoxyguanosine in human cells, *Biochemistry* 50 (2011) 2321-2329. <https://doi.org/10.1021/bi101933p>.
- [35] S. Li, L. Zhang, X. Wan, et al., Focusing on the recent progress of tea polyphenol chemistry and perspectives, *Food Sci. Hum. Well.* 11 (2022) 437-444. <https://doi.org/10.1016/j.fshw.2021.12.033>.
- [36] D.T.M. Dias, K.R. Palermo, B.P. Motta, et al., Rutin inhibits the *in vitro* formation of advanced glycation products and protein oxidation more efficiently than quercetin, *Rev. Ciênc Farm Básica Apl.* 42 (2021) e718. <https://doi.org/10.4322/2179-443X.0718>.
- [37] S. Zhang, L. Xiao, L. Lv, et al., Trapping methylglyoxal by myricetin and its metabolites in mice, *J. Agric. Food Chem.* 68 (2020) 9408-9414. <https://doi.org/10.1021/acs.jafc.0c03471>.
- [38] G. Rabbani, S.N. Ahn, Structure, enzymatic activities, glycation and therapeutic potential of human serum albumin: a natural cargo. *Int. J. Biol. Macromol.* 123 (2019) 979-990. <https://doi.org/10.1016/j.jbiomac.2018.11.053>.
- [39] S. Riaz, A. Siddiqui, F.A. Qais, et al., Inhibitory effect of baicalein against glycation in HAS: an *in vitro* approach, *J. Biomol. Struct. Dyn.* (2023) 1-13. <https://doi.org/10.1080/07391102.2023.2201856>.
- [40] H. Liu, L. Gu, Phlorotannis from Brown Algae (*Fucus vesiculosus*) inhibited the formation of advanced glycation endproducts by scavenging reactive carbonyls, *J. Agric. Food Chem.* 60 (2012) 1326-1334. <https://doi.org/10.1021/jf204112f>.
- [41] M. Reinisalo, A. Karlund, A. Koskela, et al., Molecular mechanism of defence against oxidative stress and aging-related diseases, *Oxid. Med. Cell Longev.* 2015 (2015) 340520. <https://doi.org/10.1155/2015/340520>.
- [42] L. Lv, X. Shao, L. Wang, et al., Stilbene glucoside from *Polygonum multiflorum* thub.: a novel natural inhibitor of advanced glycation end product formation by trapping of methylglyoxal, *J. Agric. Food Chem.* 58 (2010) 2239-2245. <https://doi.org/10.1021/jf904122q>.
- [43] S. Kaur, P.S. Panesar, H.K. Chopra, Citrus processing by-products: an overlooked repository of bioactive compounds, *Crit. Rev. Food Sci. Nutr.* (2021) 1943647. <https://doi.org/10.1080/10408398.2021.1943647>.

- [44] M. Wang, H. Zhao, X. Wen, et al., Citrus flavonoids and the intestinal barrier: Interactions and effects, *Compr. Rev. Food Sci. Food. Saf.* 20 (2021) 225–251. <https://doi.org/10.1111/1541-4337.12652>.
- [45] S. Li, C.Y. Lo, C.T. Ho, Hydroxylated polymethoxyflavonoids and methylated polyphenols in sweet orange peel, *J. Agri. Food Chem.* 54 (2006) 4176–4185. <https://doi.org/10.1021/jf060234n>.
- [46] S.A. Adefegha, R.D.S.P. Saccol, M.H. Jantsch, et al., Hesperidin mitigates inflammation and modulates ectoenzymes activity and some cellular processes in complete Freund's adjuvant-induced arthritic rats, *J. Pharm. Pharmacol.* 73 (2021) 1547–1561. <https://doi.org/10.1093/jpp/rgab100>.
- [47] G. Fontana, M. Bruno, F. Sottile, et al., The chemistry and the anti-inflammatory activity of polymethoxyflavonoids from citrus genus, *Antioxidants* 12 (2023) 23. <https://doi.org/10.3390/antiox12010023>.
- [48] X. Li, B. Chen, H. Xie, et al., Antioxidant structure–activity relationship analysis of five dihydrochalcones, *Molecules* 23 (2018) 1162. <https://doi.org/10.3390/molecules23051162>.
- [49] M. Wang, D. Meng, P. Zhang, et al., Antioxidant protection of nobiletin, 5-demethylnobiletin, tangeretin, and 5-demethyltangeretin from citrus peel in *Saccharomyces cerevisiae*, *J. Agri. Food Chem.* 66 (2018) 3155–3160. <https://doi.org/10.1021/acs.jafc.8b00509>.
- [50] Y.C. Tung, S. Li, Q. Huang, et al., 5-Demethylnobiletin and 5-acetoxy-6,7,8,3',4'-pentamethoxyflavone suppress lipid accumulation by activating the LKB1-AMPK pathway in 3T3-L1 preadipocytes and high fat diet-fed C57BL/6 mice, *J. Agric. Food Chem.* 127 (2016) 5211–5214. <https://doi.org/10.1021/acs.jafc.6b00706>.
- [51] J.F. Lu, M.Q. Zhu, H. Zhang, et al., Neohesperidin attenuates obesity by altering the composition of the gut microbiota in high-fat diet-fed mice, *FASB J.* 34 (2020) 12053–12071. <https://doi.org/10.1096/fj.201903102RR>.
- [52] S. Li, S. Sang, M.H. Pan, et al., Anti-inflammatory property of the urinary metabolites of nobiletin in mouse, *Bioorg. Med. Chem. Lett.* 17 (2007) 5177–5181. <https://doi.org/10.1016/j.bmcl.2007.06.096>.
- [53] S.C. Ho, C.T. Kuo, Hesperidin, nobiletin, and tangeretin are collectively responsible for the anti-neuroinflammatory capacity of tangerine peel (*Citri reticulatae* pericarpium), *Food Chem. Toxicol.* 71 (2014) 176–182. <https://doi.org/10.1016/j.fct.2014.06.014>.
- [54] N.E. Rawson, C.T. Ho, S. Li, Efficacious anti-cancer property of flavonoids from citrus peels, *Food Sci. Hum. Well.* 3 (2014) 104–109. <https://doi.org/10.1016/j.fshw.2014.11.001>.
- [55] Y.R. Li, S. Li, C.T. Ho, et al., Tangeretin derivatives, 5-acetyloxy-6,7,8,4'-tetramethoxyflavone induces G2/M arrest, apoptosis and autophagy in human non-small cell lung cancer cells *in vitro* and *in vivo*, *Cancer Biol. Therapy.* 17 (2016) 48–64. <https://doi.org/10.1080/15384047.2015.1108491>.
- [56] K.T. Tan, S. Li, Y.R. Li, et al., Synergistic anticancer effect of a combination of paclitaxel and 5-demethylnobiletin against lung cancer cell line *in vitro* and *in vivo*, *Appl. Biochem. Biotechnol.* 187 (2019) 1328–1343. <https://doi.org/10.1007/s12010-018-2869-1>.
- [57] Z. Yue, L. Wang, Y. Miyauchi, et al., Formulated citrus peel extract gold lotion improves cognitive and functional recovery from traumatic brain injury (TBI) in rats, *Food Sci. Hum. Well.* 9 (2020) 229–236. <https://doi.org/10.1016/j.fshw.2020.04.012>.
- [58] S. Okuyama, M. Morita, K. Miyoshi, et al., 3,5,6,7,8,3',4'-Heptamethoxy flavone, a citrus flavonoid, on protection against memory impairment and neuronal cell death in a global cerebral ischemia mouse model, *Neurochem. Int.* 70 (2014) 30–38. <https://doi.org/10.1016/j.neuint.2014.03.008>.
- [59] M. Hajialyani, M. H. Farzaei, J. Echeverría, et al., Hesperidin as a neuroprotective agent: a review of animal and clinical evidence, *Molecules* 24 (2019) 648. <https://doi.org/10.3390/molecules24030648>.
- [60] H. Fujiwara, J. Kimura, M. Sakamoto, et al., Nobiletin, a flavone from *Citrus depressa*, induces gene expression and increases the protein level and activity of neprilysin in SK-N-SH cells, *Can. J. Physiol. Pharmacol.* 92 (2014) 351–355. <https://doi.org/10.1139/cjpp-2013-0440>.
- [61] M. Varshney, B. Kumar, V.S. Rana, et al., An overview on therapeutic and medicinal potential of poly-hydroxy flavones viz. heptamethoxyflavone, kaempferitrin, vitexin and amentoflavone for management of Alzheimer's and Parkinson's diseases: a critical analysis on mechanistic insight, *Crit. Rev. Food Sci. Nutr.* 63 (2023) 2749–2772. <https://doi.org/10.1080/10408398.2021.1980761>.
- [62] Y.J. Chen, L. Kong, Z.Z. Tang, et al., Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathway, *Biomed. Pharmacother.* 111 (2019) 1166–1175. <https://doi.org/10.1016/j.biopha.2019.01.030>.
- [63] R. Dhanya, P. Jayamurthy, *In vitro* evaluation of antidiabetic potential of hesperidin and its aglycone hesperetin under oxidative stress in skeletal muscle cell line, *Cell Biochem. Funct.* 38 (2020) 419–427. <https://doi.org/10.1002/cbf.3478>.
- [64] R. Visvanathan, G. Williamson, Citrus polyphenols and risk of type 2 diabetes: evidence from mechanistic studies, *Crit. Rev. Food Sci. Nutr.* 63 (2023) 2178–2202. <https://doi.org/10.1080/10408398.2021.1971945>.
- [65] M. Wang, Y. Lu, Q. Wu, et al., Biotransformation and gut microbiota-mediated bioactivity of flavonols, *J. Agric. Food Chem.* 71 (2023) 8317–8331. <https://doi.org/10.1021/acs.jafc.3c01087>.
- [66] K. Nohara, V. Mallampalli, T. Nemkov, et al., Nobiletin fortifies mitochondrial respiration in skeletal muscle to promote healthy aging against metabolic challenge, *Nat. Commun.* 10 (2019) 3923. <https://doi.org/10.1038/s41467-019-11926-y>.
- [67] A. Ouyang, T.B. Garner, B.S. Fleenor, Hesperidin reverses perivascular adipose-mediated aortic stiffness with aging, *Exp. Gerontol.* 97 (2017) 68–72. <https://doi.org/10.1016/j.exger.2017.08.003>.
- [68] Y. Doki, Y. Nakazawa, N. Morishita, et al., Hesperetin treatment attenuates glycation of lens proteins and advanced-glycation end products generation, *Mol. Med. Rep.* 27 (2023) 103. <https://doi.org/10.3892/mmr.2023.12990>.
- [69] W.J. Yeh, S.M. Hsia, W.H. Lee, et al., Polyphenols with antiglycation activity and mechanisms of action: a review of recent findings, *J. Food Drug Anal.* 25 (2017) 84–92. <https://doi.org/10.1016/j.jfda.2016.10.017>.
- [70] H. Parhiz, A. Roohbakhsh, F. Soltani, et al., Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and hesperetin: an updated review of their molecular mechanisms and experimental models, *Phytother. Res.* 29 (2015) 323–331. <https://doi.org/10.1002/ptr.5256>.
- [71] A. Mas-Capdevila, J. Teichenne, C. Domenech-Coca, et al., Effect of hesperidin on cardiovascular disease risk factors: the role of intestinal microbiota on hesperidin bioavailability, *Nutrients* 12 (2020) 1488. <https://doi.org/10.3390/nu12051488>.
- [72] L. Pla-Pag, R.M. Valls, A. Pedret, et al., Effect of the consumption of hesperidin in orange juice on the transcriptomic profile of subjects with elevated blood pressure and stage 1 hypertension: a randomized controlled trial (CITRUS study), *Clinic. Nutr.* 40 (2021) 5812e5822. <https://doi.org/10.1016/j.clnu.2021.10.009>.
- [73] P.A. Miguez, S.A. Tuin, A.G. Robinson, et al., Hesperidin promotes osteogenesis and modulates collagen matrix organization and mineralization *in vitro* and *in vivo*, *Int. J. Mol. Sci.* 22 (2021) 3223. <https://doi.org/10.3390/ijms22063223>.
- [74] P. Ramlagan, P., Rondeau, C. Planes, et al., Comparative suppressing effects of black and green teas on the formation of advanced glycation end products (AGEs) and AGE-induced oxidative stress, *Food Funct.* 8 (2017) 4194–4209. <https://doi.org/10.1039/c7fo01038a>.
- [75] X. Peng, Z. Zheng, K.W. Cheng, et al., Inhibitory effect of mung bean extract and its constituents vitexin and isovitexin on the formation of advanced glycation endproducts, *Food Chem.* 106 (2008) 475–481. <https://doi.org/10.1016/j.foodchem.2007.06.016>.
- [76] X. Shao, N. Bai, K. He, et al., Apple polyphenols, phloretin and phloridzin: new trapping agents of reactive dicarbonyl species, *Chem. Res. Toxicol.* 21 (2008) 2042–2050. <https://doi.org/10.1021/tx800227v>.
- [77] L. Lv, X. Shao, H. Chen, et al., Genistein inhibits advanced glycation end product formation by trapping methylglyoxal, *Chem. Res. Toxicol.* 24 (2011) 579–586. <https://doi.org/10.1021/tx100457h>.
- [78] K. Bednarska, I. Fecka, Potential of vasoprotectives to inhibit non-enzymatic protein glycation, and reactive carbonyl and oxygen species uptake, *Int. J. Mol. Sci.* 22 (2021) 10026. <https://doi.org/10.3390/ijms221810026>.
- [79] I. Fecka, K. Bednarska, A. Kowalczyk, *In vitro* antiglycation and methylglyoxal trapping effect of peppermint leaf (*Mentha x piperita* L.) and its polyphenols, *Molecules* 28 (2023) 2865. <https://doi.org/10.3390/molecules28062865>.
- [80] N. Rabbani, P.J. Thornalley, Dicarbonyl stress in cell and tissue dysfunction contributing to ageing and disease, *Biochem. Biophys. Res. Commun.* 458 (2015) 221e226. <https://doi.org/10.1016/j.bbrc.2015.01.140>.
- [81] O. Brouwers, P.M. Niessen, I. Ferreira, et al., Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats, *J. Biol. Chem.* 286 (2011) 1374–1380. <https://doi.org/10.1074/jbc.M110.144097>.

- [82] Z. Peng, X. Yang, J. Qin, et al., Glyoxalase-1 overexpression reverses defective proangiogenic function of diabetic adipose-derived stem cells in streptozotocin-induced diabetic mice model of critical limb ischemia, *Stem Cells Transl. Med.* 6 (2017) 261–271. <https://doi.org/10.5966/sctm.2015-0380>.
- [83] X. Zhu, Y.Q. Cheng, Q. Lu, et al., Enhancement of glyoxalase 1, a polyfunctional defense enzyme, by quercetin in the brain in streptozotocin-induced diabetic rats, *Naunyn Schmiedeberg's Arch. Pharmacol.* 391 (2018) 1237–1245. <https://doi.org/10.1007/s00210-018-1543-z>.
- [84] R. Ramasamy, S.F. Yan, A.M. Schmidt, Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications, *Ann. N.Y. Acad. Sci.* 1243 (2011) 88–102. <https://doi.org/10.1111/j.1749-6632.2011.06320.x>.
- [85] Y. Hong, Z. An, Hesperidin attenuates learning and memory deficits in APP/PS1 mice through activation of Akt/Nrf2 signaling and inhibition of RAGE/NF- κ B signaling, *Arch. Pharm. Res.* 41 (2018) 655–663. <https://doi.org/10.1007/s12272-015-0662-z>.
- [86] M. Xue, M.O. Weickert, S. Qureshi, et al., Improved glycemic control and vascular function in overweight and obese subjects by glyoxalase 1 inducer formulation, *Diabetes* 65 (2016) 2282–2294. <https://doi.org/10.2337/db16-0153>.
- [87] X. Zhu, Y. Liu, Y. Liu, et al., The antidepressant-like effects of hesperidin in streptozotocin-induced diabetic rats by activating Nrf2/ARE/Glyoxalase 1 pathway, *Front. Pharmacol.* 11 (2020) 1325. <https://doi.org/10.3389/fphar.2020.01325>.
- [88] S. Ahmad, S. Mittal, R. Gulia, et al., Therapeutic role of hesperidin in collagen-induced rheumatoid arthritis through antiglycation and antioxidant activities, *Cell Biochem. Funct.* 40 (2022) 473–480. <https://doi.org/10.1002/cbf.3708>.
- [89] J.E. Lee, Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol, *Ann. Pediatr. Endocrinol. Metab.* 20 (2015) 74–78. <https://doi.org/10.6065/apem.2015.20.2.74>.
- [90] M.S. Khan, T. Rehman, M.A. Ismae, et al., Bioflavonoid (Hesperidin) restrains protein oxidation and advanced glycation end product formation by targeting AGEs and glycolytic enzymes, *Cell Biochem. Biophys.* 79 (2021) 833–844. <https://doi.org/10.1007/s12013-021-00997-8>.
- [91] X. Peng, X. Hu, K. Liu, et al., Exploring inhibitory effect and mechanism of hesperetin-Cu (II) complex against protein glycation, *Food Chem.* 416 (2023) 135801. <https://doi.org/10.1016/j.foodchem.2023.135801>.
- [92] N. Caengprasath, S. Ngamukote, K. Mäkinen, et al., The protective effects of pomelo extract (*Citrus grandis* L. Osbeck) against fructose-mediated protein oxidation and glycation, *EXCLI J.* 12 (2013) 491–502.
- [93] M.Y. Ali, S. Zaib, M.M. Rahman, et al., Poncirin, an orally active flavonoid exerts antidiabetic complications and improves glucose uptake activating PI3K/Akt signaling pathway in insulin resistant C2C12 cells with anti-glycation capacities, *Bioorg. Chem.* 102 (2020) 104061. <https://doi.org/10.1016/j.bioorg.2020.104061>.
- [94] G. Yang, X. Xia, H. Zhong, et al., Protective effect of tangeretin and 5-hydroxy-6,7,8,3',4'-pentamethoxyflavone on collagen-induced arthritis by inhibiting autophagy via activation of the ROS-AKT/mTOR signaling pathway, *J. Agric. Food Chem.* 69 (2021) 259–266. <https://doi.org/10.1021/acs.jafc.0c06801>.
- [95] G. Yang, C.C. Lin, Y. Yang, et al., Nobiletin prevents TMAO-induced vascular inflammation via inhibition of the NF- κ B/MAPK pathways, *J. Agric. Food Chem.* 67 (2019) 6169–6176. <https://doi.org/10.1021/acs.jafc.9b01270>.
- [96] J. Kimura, K. Shimizu, K. Kajima, et al., Nobiletin reduces intracellular and extracellular β -amyloid in iPS cell-derived Alzheimer's disease model neurons, *Biol. Pharm. Bull.* 41 (2018) 451–457. <https://doi.org/10.1248/bpb.b17-00364>.
- [97] A. Nakajima, Y. Ohizumi, K. Yamada, Anti-dementia activity of nobiletin, a citrus flavonoid: a review of animal studies, *Clin. Psychopharmacol. Neurosci.* 12 (2014) 75–82. <https://doi.org/10.9758/cpn.2014.12.2.75>.
- [98] A. Upadhyay, E. Tuentner, A. Amin, et al., 5-O-Demethylnobiletin, a polymethoxylated flavonoid, from *Citrus depressa* Hayata peel prevents protein glycation, *J. Funct. Foods* 11 (2014) 243–249. <https://doi.org/10.1016/j.jff.2014.10.012>.
- [99] M.C. Lai, W.Y. Liu, S.S. Liou, et al., The citrus flavonoid hesperetin encounters diabetes-mediated Alzheimer-type neuropathologic changes through relieving advanced glycation end-products inducing endoplasmic reticulum stress, *Nutrients* 14 (2022) 745. <https://doi.org/10.3390/nu14040745>.
- [100] M.C. Lai, W.Y. Liu, S.S. Liou, et al., Diosmetin targeted at peroxisome proliferator-activated receptor gamma alleviates advanced glycation end products induced neuronal injury, *Nutrients* 14 (2022) 2248. <https://doi.org/10.3390/nu14112248>.
- [101] F. Fang, L.F. Lue, S. Yan, et al., RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease, *FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.* 24 (2010) 1043–1055. <https://doi.org/10.1096/fj.09-139634>.
- [102] Y. Zhang, Z. Luo, L. Ma, et al., Resveratrol prevents the impairment of advanced glycosylation end products (AGE) on macrophage lipid homeostasis by suppressing the receptor for age via peroxisome proliferator-activated receptor gamma activation, *Int. J. Mol. Med.* 25 (2010) 729–734. <https://doi.org/10.3892/ijmm.00000398>.
- [103] M. Kastle, T. Grune, Protein oxidative modification in the aging organism and the role of the ubiquitin proteasomal system, *Curr. Pharm. Des.* 17 (2011) 4007–4022. <https://doi.org/10.2174/138161211798764898>.
- [104] J. Raupbach, C. Otta, J. Koenig, et al., Proteasomal degradation of glycated proteins depends on substrate unfolding: preferred degradation of moderately modified myoglobin, *Free Radic. Biol. Med.* 152 (2020) 516–524. <https://doi.org/10.1016/j.freeradbiomed.2019.11.024>.
- [105] Z. Svikle, B. Peterfelde, N. Sjakste, et al., Ubiquitin-proteasome system in diabetic retinopathy, *PeerJ* 10 (2022) e13715. <https://doi.org/10.7717/peerj.13715>.
- [106] A. Taylor, Mechanistically linking age-related diseases and dietary carbohydrate via autophagy and the ubiquitin proteolytic systems, *Autophagy* 8 (2012) 1404–1406. <https://doi.org/10.4161/auto.21150>.
- [107] D.J. Eisermann, U. Wenzel, E. Fitzenberger, Inhibition of chaperone-mediated autophagy prevents glucotoxicity in the *Caenorhabditis elegans mev-1* mutant by activation of the proteasome, *Biochem. Biophys. Res. Commun.* 484 (2017) 171–175. <https://doi.org/10.1016/j.bbrc.2017.01.043>.
- [108] A. Takahashi, Y. Takabatake, T. Kimura, et al., Autophagy inhibits the accumulation of advanced glycation end products by promoting lysosomal biogenesis and function in the kidney proximal tubules, *Diabetes* 66 (2017) 1359–1372. <https://doi.org/10.2337/db16-0397>.
- [109] K.M. Choi, K.A. Han, H.J. Ahn, et al., Effects of exercise on sRAGE levels and cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled trial, *J. Clin. Endocrinol. Metab.* 97 (2012) 3751–3758. <https://doi.org/10.1210/jc.2012-1951>.
- [110] M.H. Macías-Cervantes, J.M.D. Rodríguez-Soto, J. Uribarri, et al., Effect of an advanced glycation end product-restricted diet and exercise on metabolic parameters in adult overweight men, *Nutr. Burbank Los Angel. City. Calif* 31 (2015) 446–451. <https://doi.org/10.1016/j.nut.2014.10.004>.
- [111] S. Rowan, E. Bejarano, A. Taylor, Mechanistic targeting of advanced glycation end-products in age-related diseases, *Biochim. Biophys. Acta Mol. Basis Dis.* 1864 (2018) 3631–3643. <https://doi.org/10.1016/j.bbadis.2018.08.036>.
- [112] C.Y. Chen, J.Q. Zhang, L. Li, et al., Advanced glycation end products in the skin: molecular mechanisms, methods of measurement, and inhibitory pathways, *Front. Med.* 9 (2022) 837222. <https://doi.org/10.3389/fmed.2022.837222>.
- [113] S. Sarmah, A. Goswami, V.K. Belwal, et al., Mitigation of ribose and glyoxal induced glycation, AGEs formation and aggregation of human serum albumin by citrus fruit phytochemicals naringin and naringenin: an insight into their mechanism of action, *Food Res. Int.* 157 (2022) 111358. <https://doi.org/10.1016/j.foodres.2022.111358>.
- [114] K. Kishan Srikanth, J.A. Orrick, Biochemistry, polyol or sorbitol pathways. In: NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. StatPearls Publishing; 2023. <https://www.ncbi.nlm.nih.gov/books/NBK576381>.
- [115] M.S. Khan, F.A. Qais, M.T. Rehman, et al., Mechanistic inhibition of non-enzymatic glycation and aldose reductase activity by naringenin: binding, enzyme kinetics and molecular docking analysis. *Int. J. Biol. Macromol.* 159 (2020) 87–97. <https://doi.org/10.1016/j.ijbiomac.2020.04.226>.